Open access
Open access
Powered by Google Translator Translator

Daily Archives: March 9, 2023

WHO Meta-Analysis | Saturated fat and trans-fat intakes and their replacement with other macronutrients

9 Mar, 2023 | 14:24h | UTC

Saturated fat and trans-fat intakes and their replacement with other macronutrients: a systematic review and meta-analysis of prospective observational studies – World Health Organization

 

Commentary on Twitter

 

Crossover RCT | Atrial pacing to increase exercise HR did not improve performance in HFpEF patients with chronotropic incompetence

9 Mar, 2023 | 14:22h | UTC

Summary: The RAPID-HF randomized clinical trial investigated whether implanting and programming a pacemaker for rate-adaptive atrial pacing would improve exercise performance in patients with heart failure with preserved ejection fraction (HFpEF) and chronotropic incompetence.

The study involved 29 patients with symptomatic HFpEF and chronotropic incompetence who underwent pacemaker implantation for the study and then were randomized to atrial rate responsive pacing or no pacing for four weeks, followed by a four-week washout period and then crossover for an additional four weeks.

The study found that atrial pacing increased early and peak exercise heart rate, but there was no improvement in exercise performance or quality of life. Despite a higher exercise heart rate, there was no increase in exercise cardiac output due to a decrease in stroke volume. Moreover, pacemaker implantation was associated with adverse events.

Article: Rate-Adaptive Atrial Pacing for Heart Failure With Preserved Ejection Fraction: The RAPID-HF Randomized Clinical Trial – JAMA (free for a limited period)

Editorial: Rate-Adaptive Pacing for Heart Failure With Preserved Ejection Fraction – JAMA (free for a limited period)

Commentaries:

RAPID-HF: Rate-Adaptive Pacing Doesn’t Help in HFpEF – TCTMD

Atrial Pacing for HFpEF Shows Lack of Benefit on Exercise Capacity – HCP Live

 

Commentary on Twitter

 

Evidence Analysis | Menière’s disease: experience, evidence gaps & treatment choices

9 Mar, 2023 | 14:21h | UTC

Menière’s disease: experience, evidence gaps & treatment choices – Evidently Cochrane

New Cochrane Reviews:

Systemic pharmacological interventions for Ménière’s disease – Cochrane Library

Intratympanic gentamicin for Ménière’s disease – Cochrane Library

Intratympanic corticosteroids for Ménière’s disease – Cochrane Library

Positive pressure therapy for Ménière’s disease – Cochrane Library

Lifestyle and dietary interventions for Ménière’s disease – Cochrane Library

Surgical interventions for Ménière’s disease – Cochrane Library

 

Consensus Recommendations | Spinal tumors

9 Mar, 2023 | 14:15h | UTC

Spinal tumours: recommendations of the Polish Society of Spine Surgery, the Polish Society of Oncology, the Polish Society of Neurosurgeons, the Polish Society of Oncologic Surgery, the Polish Society of Oncologic Radiotherapy, and the Polish Society of Orthopaedics and Traumatology – European Spine Journal

 

Consensus bundle on cardiac conditions in obstetric care

9 Mar, 2023 | 14:14h | UTC

Alliance for Innovation on Maternal Health: Consensus Bundle on Cardiac Conditions in Obstetric Care – Obstetrics & Gynecology

 

SR | Spinal cord stimulation for low back pain provides no sustained clinical benefits compared to placebo

9 Mar, 2023 | 14:12h | UTC

Summary: Spinal cord stimulation (SCS) is a surgical procedure used to treat persistent low back pain by sending electrical signals via implanted electrodes into the spinal cord. The review included 13 studies (randomized controlled trials and cross‐over trials) with 699 participants.

Most of the studies were focused on short-term effects (less than one month), but the review found it is uncertain whether spinal cord stimulation can improve outcomes in the immediate term compared with placebo. At six months, SCS probably does not improve back or leg pain, function, or quality of life compared with placebo, with moderate certainty of evidence. Adverse events were also reported, including infections, neurological damage, and lead migration requiring repeated surgery.

The review concluded that the data does not support the use of SCS to manage low back pain outside a clinical trial. Current evidence suggests SCS probably does not have sustained clinical benefits that would outweigh the costs and risks of this surgical intervention.

Article: Spinal cord stimulation for low back pain – Cochrane Library

Summary: Spinal cord stimulation for low back pain – Cochrane Library

 

Commentary from the author on Twitter

 

M-A | Opioids for breathlessness in heart failure have no significant benefits and increase adverse effects

9 Mar, 2023 | 14:11h | UTC

Summary: The study aimed to assess the effectiveness of opioids in treating breathlessness in patients with heart failure and to evaluate their adverse effects. The authors conducted a systematic review of randomized controlled trials (RCTs) and included eight studies with 271 patients.

The results showed that opioids did not provide significant benefits in managing breathlessness in advanced HF and significantly increased the risk of adverse events such as nausea, vomiting, and constipation.

The authors suggest that opioids should be considered only as a last resort when other interventions have failed or in emergency situations.

Article: Effect of opioids for breathlessness in heart failure: a systematic review and meta-analysis – Heart

 

RCT | Assessment of a text message–based smoking cessation intervention for adult smokers

9 Mar, 2023 | 14:09h | UTC

Assessment of a Text Message–Based Smoking Cessation Intervention for Adult Smokers in China: A Randomized Clinical Trial – JAMA Network Open

 

Commentary on Twitter

 

Single-arm study | Gene therapy with Etranacogene Dezaparvovec for Hemophilia B

9 Mar, 2023 | 14:07h | UTC

Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Gene Therapy Beneficial for Patients With Hemophilia B – HealthDay

 

M-A | Tailoring the optimal duration of the extended adjuvant endocrine therapy in patients with early-stage breast cancer

9 Mar, 2023 | 14:06h | UTC

Tailoring the optimal duration of the extended adjuvant endocrine therapy in patients with early-stage breast cancer. A systematic review and meta-analysis of randomized clinical trials – The Breast

 

Review | Treatment of systemic sclerosis

9 Mar, 2023 | 14:05h | UTC

State-of-the-art evidence in the treatment of systemic sclerosis – Nature Reviews Rheumatology

 

Practice Guide | Acquiring tissue for advanced lung cancer diagnosis and comprehensive biomarker testing

9 Mar, 2023 | 14:04h | UTC

Acquiring tissue for advanced lung cancer diagnosis and comprehensive biomarker testing: A National Lung Cancer Roundtable best-practice guide – CA: A Cancer Journal for Clinicians

 

RCT/extended follow-up | Lenvatinib plus pembrolizumab vs. sunitinib in patients with advanced renal cell carcinoma

9 Mar, 2023 | 14:03h | UTC

Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study – The Lancet Oncology (link to abstract – $ for full-text)

Original Study: Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma – New England Journal of Medicine (link to abstract – $ for full-text)

 

Commentary on Twitter

 

SR | There is insufficient evidence to recommend pharmacological treatments for central sleep apnea in adults

9 Mar, 2023 | 14:01h | UTC

Pharmacological treatment for central sleep apnoea in adults – Cochrane Library

Summary: Medicines for central sleep apnoea in adults – Cochrane Library

 

Cohort Study | Personalized progression prediction in patients with MGUS or smouldering multiple myeloma

9 Mar, 2023 | 13:59h | UTC

Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study – The Lancet Haematology

Invited Commentary: The PANGEA model: catching the drift from precursor conditions to myeloma in individual patients – The Lancet Haematology

 

Commentary from the author on Twitter (thread – click for more)

 

Ileal pouch-anal anastomosis in the older adult: a review of postoperative outcomes and pouchitis treatment

9 Mar, 2023 | 14:00h | UTC

Ileal Pouch-Anal Anastomosis in the Older Adult: a Review of Postoperative Outcomes and Pouchitis Treatment – Current Treatment Options in Gastroenterology

 

RCT | Home telemonitoring vs. hospital care in complicated pregnancies in the Netherlands

9 Mar, 2023 | 13:58h | UTC

Home telemonitoring versus hospital care in complicated pregnancies in the Netherlands: a randomised, controlled non-inferiority trial (HoTeL) – The Lancet Digital Health

 

Commentary on Twitter

 

M-A | Efficacy of mesalamine in irritable bowel syndrome

9 Mar, 2023 | 13:56h | UTC

Systematic Review and Meta-analysis: Efficacy of Mesalamine in Irritable Bowel Syndrome – Clinical Gastroenterology and Hepatology

 

Review | Nutritional management of the infant with chronic kidney disease stages 2–5 and on dialysis

9 Mar, 2023 | 14:18h | UTC

Nutritional management of the infant with chronic kidney disease stages 2–5 and on dialysis – Pediatric Nephrology

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.